Therefore, PAF-AH up-regulation arose as a specific thrombotic risk marker in patients carrying aβ2GPI antibodies and is not generally associated with other aPL antibodies possibly implicated in APS manifestations, but further studies are needed to confirm this observation. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.